Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line

Chemical and Pharmaceutical Bulletin

Volumn 61, Issue 4, 2013, Pages 405-410

  Abadi, Ashraf Hassan ^a   Hany, Marwa Saeed ^a   Elsharif, Shimaa Awadain ^a   Eissa, Amal Abdel Haleem ^b   De Wayne Gary, Bernard ^c   Tinsley, Heather Nicole ^d   Piazza, Gary Anthony ^c  

^a German University in Cairo   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d UNIVERSITY OF MONTEVALLO   (United States)

Author keywords

Phosphodiesterase 3; Pyridine derivative; Substrate modulation

Indexed keywords

2 AMINO 6 (3 BROMOPHENYL) 4 (2 ETHOXYPHENYL)NICOTINONITRILE; 2 AMINO 6 (3 BROMOPHENYL) 4 (2 METHOXYPHENYL)NICOTINONITRILE; 2 AMINO 6 (4' BROMOBIPHENYL 4 YL) 4 (2 METHOXYPHENYL)NICOTINONITRILE; 6 (2 BROMOPHENYL) 4 (2 CHLOROPHENYL) 2 OXO 1,2 DIHYDROPYRIDINE 3 CARBONITRILE; 6 (2 BROMOPHENYL) 4 (2 ETHOXYPHENYL) 2 OXO 1,2 DIHYDROPYRIDINE 3 CARBONITRILE; 7 (3 BROMOPHENYL) 5 (2 ETHOXYPHENYL)PYRIDO[2,3 D]PYRIMIDIN 4 AMINE; 7 (3 BROMOPHENYL) 5 (2 METHOXYPHENYL)PYRIDO[2,3 DEXTRO]PYRIMIDIN 4(3H) ONE; CILOSTAMIDE; CYCLIC GMP; ENOXIMONE; LIXAZINONE; MILRINONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLORECTAL CANCER; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; MODULATION; TACHYCARDIA;

BINDING SITES; CATALYTIC DOMAIN; CELL PROLIFERATION; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIZATION; HT29 CELLS; HUMANS; HYDROLYSIS; MOLECULAR DOCKING SIMULATION; PHOSPHODIESTERASE 3 INHIBITORS; PROTEIN BINDING; PYRIDINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84876458159     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.c12-00993     Document Type: Article

References (11)

1. Murata T., Shimizu K., Hiramoto K., Tagawa T., Cardiovasc. Hematol. Agents Med. Chem., 7, 206-211 (2009).
2. Zhang K. Y., Card G. L., Suzuki, Y., Artis D. R., Fong D., Gillette S., Hsieh D., Neiman J., West B. L., Zhang C., Milburn M. V., Kim S. H., Schlessinger J., Bollag G. A., Mol. Cell, 15, 279-286 (2004).
3. Ke H., Wang H., Curr. Top. Med. Chem., 7, 391-403 (2007).
4. Hambleton R., Krall J., Tikishvili E., Honeggar M., Ahmad F., Manganiello V. C., Movsesian M. A., J. Biol. Chem., 280, 39168-39174 (2005).
5. Hayashi H., Sudo T., Thromb. Haemost., 102, 327-335 (2009).
6. Koka S., Das A., Zhu S. G., Durrant D., Xi L., Kukreja R. C., J. Pharmacol. Exp. Ther., 334, 1023-1030 (2010).
7. Tinsley H. N., Gary B. D., Keeton A. B., Zhang W., Abadi A. H., Reynolds R. C., Piazza G. A., Mol. Cancer Ther., 8, 3331-3340 (2009).
8. Abadi A. H., al-Khamees H. A., Arch. Pharm. (Weinheim), 331, 319-324 (1998).
9. Abadi A. H., Abouel-Ella D. A., Lehmann J., Tinsley H. N., Gary B. D., Piazza G. A., Abdel-Fattah M. A. O., Eur. J. Med. Chem., 45, 90-97 (2010).
10. MOE, Chemical Computing Group Inc., Montreal.: http://www.chemcomp/com.
11. Scapin G., Patel S. B., Chung C., Varnerin J. P., Edmondson S. D., Mastracchio A., Parmee E. R., Singh S. B., Becker J. W., Van der Ploeg L. H., Tota M. R., Biochemistry, 43, 6091-6100 (2004).